{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:16Z","timestamp":1789140676707,"version":"build-2803163510"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chemotherapy-induced myelosuppression (CIM), including neutropenia, thrombocytopenia, and anaemia, is a common and potentially life-threatening complication in breast cancer patients. Despite the clinical availability of both short-acting and long-acting Granulocyte Colony-Stimulating Factors (G-CSFs) for primary prophylaxis, evidence supporting the selection of the most appropriate therapeutic agent based on individual characteristics remains limited. This study employs a systematic review and network meta-analysis (NMA) to directly compare individualized G-CSF formulations, aiming to establish a definitive efficacy and safety ranking for clinical guidance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Randomised controlled trials of long-acting versus short-acting G-CSF therapy (both originator and biosimilar) in breast cancer patients with CIM will be identified via a search of PubMed, Embase, Web of Science, Cochrane Central Register for Controlled Trials, ClinicalTrials.gov, and the Chinese literature databases, CNKI, Wanfang, VIP, and SinoMed, from inception to 30 September 2025. The main outcomes include the myelosuppression incidence\/severity (e.g., neutropenia, thrombocytopenia), chemotherapy relative dose intensity (or dose reductions\/delays due to neutropenia), overall survival, Eastern Cooperative Oncology Group (ECOG) performance status, infection-related mortality, and adverse events. Two independent reviewers will perform document screening, study selection, and data extraction. The methodological quality of the included studies will be assessed using the Cochrane Risk of Bias tool (V.2.0). The certainty of the evidence will be rated using the Grading of Recommendations, Assessment, Development, and Evaluation System.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This systematic review is based on already published data, so it does not require ethical approval. The findings of this review will be submitted to peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1764945","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:18:55Z","timestamp":1774351135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy and safety of individual short-acting versus long-acting granulocyte colony-stimulating factors, including biosimilars, for primary prophylaxis of chemotherapy-induced myelosuppression in breast cancer patients: a systematic review and network meta-analysis protocol"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoyun","family":"Bi","sequence":"first","affiliation":[{"name":"Sleep Medicine Center, Longhua Hospital Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Shu","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangmin","family":"Tang","sequence":"additional","affiliation":[{"name":"School of Rehabilitation Science, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yin","sequence":"additional","affiliation":[{"name":"Sleep Medicine Center, Longhua Hospital Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelai","family":"Chen","sequence":"additional","affiliation":[{"name":"Sleep Medicine Center, Longhua Hospital Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-025-07746-y","article-title":"Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis","volume":"212","author":"Liutti","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020189","article-title":"Implications of breast cancer chemotherapy-induced inflammation on the gut, liver, and central nervous system","volume":"9","author":"Brown","year":"2021","journal-title":"Biomedicines"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000449226","article-title":"Incidence and predictors of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy in Korea","volume":"91","author":"Kim","year":"2016","journal-title":"Oncology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1613199","article-title":"The use of granulocyte colony-stimulating factors in the management of breast cancer patients","volume":"15","author":"Ba\u0142ata","year":"2025","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-025-01479-y","article-title":"Efbemalenograstim alfa, an fc fusion protein, long\u2212Acting granulocyte colony-stimulating factor for reducing the risk of chemotherapy-induced neutropenia: results of a phase II randomized, multicenter, open\u2212Label trial","volume":"45","author":"Ji","year":"2025","journal-title":"Clin Drug Investig"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021.1188","article-title":"Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria","volume":"15","author":"Salako","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1965725","article-title":"New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils","volume":"26","author":"Theyab","year":"2021","journal-title":"Hematology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156759","article-title":"Old drug, new use: Recent advances for G-CSF","volume":"184","author":"Yan","year":"2024","journal-title":"Cytokine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3842-1","article-title":"Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations","volume":"25","author":"Aapro","year":"2017","journal-title":"Supportive Care Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: american society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors (Version 1.2025)","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1009-0460.2021.07.011","article-title":"Chinese Society of Clinical Oncology (CSCO) guidelines for standardized management of tumor chemoradiotherapy-related neutropenia","volume":"26","author":"Ma","year":"2021","journal-title":"Chin Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2017.10.034","article-title":"Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients","volume":"89","author":"Botteri","year":"2018","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"Cd007913","DOI":"10.1002\/14651858.CD007913.pub2","article-title":"Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients","volume":"10","author":"Renner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0798-6","article-title":"Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia","volume":"35","author":"Cornes","year":"2018","journal-title":"Adv Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05603-w","article-title":"Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis","volume":"28","author":"Li","year":"2020","journal-title":"Support Care Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02570-8","article-title":"Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022","volume":"29","author":"Nozawa","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2457-z","article-title":"Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review","volume":"23","author":"Pfeil","year":"2015","journal-title":"Support Care Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-016-4028-0","article-title":"Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review","volume":"161","author":"Fernandes","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-023-02300-6","article-title":"Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment: An expert view","volume":"136","author":"Gasc\u00f3n","year":"2024","journal-title":"Wien Klin Wochenschr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4609-6","article-title":"Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study","volume":"168","author":"Xie","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1186\/s12885-024-12892-5","article-title":"A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12885-023-11198-2","article-title":"Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients","volume":"23","author":"Jiang","year":"2023","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"Bmj"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12874-024-02310-6","article-title":"Identify the most appropriate imputation method for handling missing values in clinical structured datasets: a systematic review","volume":"24","author":"Afkanpour","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19319","article-title":"Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: A systematic review and meta-analysis","volume":"320","author":"Gregori","year":"2018","journal-title":"Jama"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"Bmj"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.zefq.2012.06.013","article-title":"GRADE guidelines: 3. Rating the quality of evidence (confidence in the estimates of effect)","volume":"106","author":"Meerpohl","year":"2012","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1678","article-title":"Avoiding common mistakes in meta-analysis: Understanding the distinct roles of Q, I-squared, tau-squared, and the prediction interval in reporting heterogeneity","volume":"15","author":"Borenstein","year":"2024","journal-title":"Res Synthesis Methods"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e106553","DOI":"10.1136\/bmjopen-2025-106553","article-title":"Pharmacological interventions in IgA nephropathy: protocol for a living systematic review and network meta-analysis","volume":"15","author":"Bagchi","year":"2025","journal-title":"BMJ Open"},{"key":"B34","article-title":"Cochrane Handbook for Systematic Reviews of Interventions (Version 6.5)","author":"Higgins","year":"2024","journal-title":"Cochrane."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I(2) is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e093728","DOI":"10.1136\/bmjopen-2024-093728","article-title":"Comparative efficacy and safety of pharmacological agents for chronic low back pain: A systematic review and bivariate bayesian network meta-analysis protocol","volume":"15","author":"Aremu","year":"2025","journal-title":"BMJ Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"key":"B38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.35566\/jbds\/v2n2\/p3","article-title":"The performances of Gelman-Rubin and Geweke\u2019s convergence diagnostics of Monte Carlo Markov chains in Bayesian analysis","volume":"2","author":"Du","year":"2022","journal-title":"J Behav Data Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"Gelman A","year":"1992","journal-title":"Stat Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwab278","article-title":"Introducing the treatment hierarchy question in network meta-analysis","volume":"191","author":"Salanti","year":"2022","journal-title":"Am J Epidemiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.7010","article-title":"Risk of febrile neutropenia associated with select myelosuppressive chemotherapy regimens in a large community-based oncology practice","volume":"15","author":"Li","year":"2017","journal-title":"J Natl Compr Cancer Netw"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764945\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:18:58Z","timestamp":1774351138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764945\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":45,"alternative-id":["10.3389\/fonc.2026.1764945"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1764945","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"article-number":"1764945"}}